Affiliations: [a] Department of Breast Surgery, Mater Misericordiae University Hospital, Dublin, Ireland | [b] Department of Breast Radiology, Mater Misericordiae University Hospital, Dublin, Ireland | [c] Department of Cellular Pathology, Mater Misericordiae University Hospital, Dublin, Ireland
Correspondence:
[*]
Corresponding author: E.C. Dunne, Department of Breast Surgery, Mater Misericordiae University Hospital, Dublin, Ireland. E-mail: emmadunne@rcsi.ie
Abstract: INTRODUCTION:Atypical intraductal epithelial proliferation (AIDEP) is a breast lesion categorised as “indeterminate” if identified on core needle biopsy (CNB). The rate at which these lesions are upgraded following diagnostic excision varies in the literature. Women diagnosed with AIDEP are thought to be at increased risk of breast cancer. Our aim was to identify the rate of upgrade to invasive or in situ carcinoma in a group of patients diagnosed with AIDEP on screening mammography and to quantify their risk of subsequent breast cancer. METHODS:We conducted a retrospective review of a prospectively maintained database containing all patients diagnosed with AIDEP on CNB between 2005 and 2012 in an Irish breast screening centre. Basic demographic data was collected along with details of the original CNB result, rate of upgrade to carcinoma and details of any subsequent cancer diagnoses. RESULTS:In total 113 patients were diagnosed with AIDEP on CNB during the study period. The upgrade rate on diagnostic excision was 28.3% (n = 32). 6.2% (n = 7) were upgraded to invasive cancer and 22.1% (n = 25) to DCIS. 81 patients were not upgraded on diagnostic excision and were offered 5 years of annual mammographic surveillance. 9.88% (8/81) of these patients went on to receive a subsequent diagnosis of malignancy. The mean time to diagnosis of these subsequent cancers was 65.41 months (range 20.18–145.21). CONCLUSION:Our data showing an upgrade rate of 28% to carcinoma reflects recently published data and we believe it supports the continued practice of excising AIDEP to exclude co-existing carcinoma.
Keywords: Biopsy/image-guided intervention, population screening, pathology of premalignant lesions
DOI: 10.3233/BD-201031
Journal: Breast Disease, vol. 40, no. 3, pp. 155-160, 2021
